Repligen’s Promising Potential in 2011
Seeking Alpha | December 24, 2010 | By Patrick Crutcher
Repligen Corporation (RGEN) is another attractive biotech that has revenues, cash and pending data in early 2011. With pending Phase 2 and Phase 3 data, Repligen seems set for a transformative 2011. Specifically, it has two important clinical catalysts in Q1 2011: Phase 3 data for RG1068 (pancreatic imaging agent) and Phase 2b data for its bipolar drug (RG2417). Both of these catalysts have the potential to take RGEN to new levels in 2011.
Click HERE or on the image below to read more…